Logo image of SSKN

STRATA SKIN SCIENCES INC (SSKN) Stock Fundamental Analysis

NASDAQ:SSKN - US86272A3059 - Common Stock

2.1 USD
+0.45 (+27.27%)
Last: 8/27/2025, 8:18:59 PM
2.13 USD
+0.03 (+1.43%)
After Hours: 8/27/2025, 8:18:59 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SSKN. SSKN was compared to 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of SSKN have multiple concerns. While showing a medium growth rate, SSKN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SSKN has reported negative net income.
In the past year SSKN had a positive cash flow from operations.
SSKN had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SSKN reported negative operating cash flow in multiple years.
SSKN Yearly Net Income VS EBIT VS OCF VS FCFSSKN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

SSKN's Return On Assets of -26.71% is in line compared to the rest of the industry. SSKN outperforms 44.86% of its industry peers.
With a Return On Equity value of -342.83%, SSKN is not doing good in the industry: 79.46% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -26.71%
ROE -342.83%
ROIC N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
SSKN Yearly ROA, ROE, ROICSSKN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Gross Margin of SSKN (58.44%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SSKN has declined.
SSKN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
SSKN Yearly Profit, Operating, Gross MarginsSSKN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SSKN has been increased compared to 1 year ago.
The number of shares outstanding for SSKN has been reduced compared to 5 years ago.
Compared to 1 year ago, SSKN has a worse debt to assets ratio.
SSKN Yearly Shares OutstandingSSKN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SSKN Yearly Total Debt VS Total AssetsSSKN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -9.54, we must say that SSKN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.54, SSKN is doing worse than 78.38% of the companies in the same industry.
SSKN has a Debt/Equity ratio of 5.71. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of SSKN (5.71) is worse than 91.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.71
Debt/FCF N/A
Altman-Z -9.54
ROIC/WACCN/A
WACC9.79%
SSKN Yearly LT Debt VS Equity VS FCFSSKN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

SSKN has a Current Ratio of 1.05. This is a normal value and indicates that SSKN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of SSKN (1.05) is worse than 89.73% of its industry peers.
A Quick Ratio of 0.87 indicates that SSKN may have some problems paying its short term obligations.
The Quick ratio of SSKN (0.87) is worse than 84.86% of its industry peers.
Industry RankSector Rank
Current Ratio 1.05
Quick Ratio 0.87
SSKN Yearly Current Assets VS Current LiabilitesSSKN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SSKN have decreased strongly by -16.87% in the last year.
The Revenue has been growing slightly by 0.61% in the past year.
The Revenue has been growing slightly by 1.22% on average over the past years.
EPS 1Y (TTM)-16.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1900%
Revenue 1Y (TTM)0.61%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-9.15%

3.2 Future

Based on estimates for the next years, SSKN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.30% on average per year.
SSKN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.04% yearly.
EPS Next Y37.76%
EPS Next 2Y28.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-1.34%
Revenue Next 2Y4.04%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SSKN Yearly Revenue VS EstimatesSSKN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M
SSKN Yearly EPS VS EstimatesSSKN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SSKN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SSKN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SSKN Price Earnings VS Forward Price EarningsSSKN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

SSKN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. SSKN is cheaper than 74.59% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 20.85
SSKN Per share dataSSKN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as SSKN's earnings are expected to grow with 28.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.3%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SSKN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STRATA SKIN SCIENCES INC

NASDAQ:SSKN (8/27/2025, 8:18:59 PM)

After market: 2.13 +0.03 (+1.43%)

2.1

+0.45 (+27.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)11-11 2025-11-11/amc
Inst Owners29.54%
Inst Owner Change-1.86%
Ins Owners3.91%
Ins Owner Change0%
Market Cap8.76M
Analysts85
Price Target8.16 (288.57%)
Short Float %1.68%
Short Ratio1.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-140.67%
Min EPS beat(2)-271.14%
Max EPS beat(2)-10.2%
EPS beat(4)1
Avg EPS beat(4)-50.91%
Min EPS beat(4)-271.14%
Max EPS beat(4)95.8%
EPS beat(8)2
Avg EPS beat(8)-84.42%
EPS beat(12)5
Avg EPS beat(12)-45.36%
EPS beat(16)8
Avg EPS beat(16)-19.44%
Revenue beat(2)1
Avg Revenue beat(2)-1.84%
Min Revenue beat(2)-8.28%
Max Revenue beat(2)4.61%
Revenue beat(4)3
Avg Revenue beat(4)2.19%
Min Revenue beat(4)-8.28%
Max Revenue beat(4)11.4%
Revenue beat(8)3
Avg Revenue beat(8)-5.33%
Revenue beat(12)6
Avg Revenue beat(12)-1.18%
Revenue beat(16)8
Avg Revenue beat(16)-0.34%
PT rev (1m)-11.11%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-35.49%
EPS NY rev (3m)-60.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-4.33%
Revenue NY rev (3m)-8.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.26
P/FCF N/A
P/OCF 19.81
P/B 3.28
P/tB N/A
EV/EBITDA 20.85
EPS(TTM)-2.84
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)0.11
OCFY5.05%
SpS8.06
BVpS0.64
TBVpS-1.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.71%
ROE -342.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.44%
FCFM N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
F-Score5
Asset Turnover0.98
Health
Industry RankSector Rank
Debt/Equity 5.71
Debt/FCF N/A
Debt/EBITDA 20.36
Cap/Depr 21.07%
Cap/Sales 3.3%
Interest Coverage N/A
Cash Conversion 59.09%
Profit Quality N/A
Current Ratio 1.05
Quick Ratio 0.87
Altman-Z -9.54
F-Score5
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)60.99%
Cap/Depr(5y)68.15%
Cap/Sales(3y)9.91%
Cap/Sales(5y)10.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1900%
EPS Next Y37.76%
EPS Next 2Y28.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.61%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-9.15%
Revenue Next Year-1.34%
Revenue Next 2Y4.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year139.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y89.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y122.55%
OCF growth 3Y-50.07%
OCF growth 5Y-39.02%